4.6 Review

Review of Voltage-gated Calcium Channel α2δ Subunit Ligands for the Treatment of Chronic Neuropathic Pain and Insight into Structure-activity Relationship (SAR) by Pharmacophore Modeling

Journal

CURRENT MEDICINAL CHEMISTRY
Volume 29, Issue 30, Pages 5097-5112

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867329666220407093727

Keywords

Voltage-gated calcium channel; alpha 2 delta subunit; neuropathic pain; structure-activity relationship (SAR); pharmacophore modeling; gabapentinoids

Funding

  1. Guangdong Provincial Natural Science Foundation [2021A1515010197]
  2. Zhongshan Municipal Natural Science Foundation [200805173640573]

Ask authors/readers for more resources

This study reviewed the latest progress in the discovery and development of gabapentinoids for the treatment of chronic neuropathic pain (NP). The structure-activity relationship (SAR) of gabapentinoids was analyzed through pharmacophore modeling. The findings provide valuable insights for the future design of novel therapeutic agents targeting the voltage-gated calcium channel (VGCC) alpha 2 delta subunit.
Background: Neuropathic pain (NP) is a complex symptom related to nerve damage. The discovery of new drugs for treating chronic NP has been continuing for several decades, while more progress is still needed because of the unsatisfactory efficacy and the side effects of the currently available drugs. Among all the approved drugs for chronic NP, voltage-gated calcium channel (VGCC) alpha 2 delta subunit ligands, also known as gabapentinoids, are among the first-line treatment and represent a class of efficacious and relatively safe therapeutic agents. However, new strategies are still needed to be explored due to the unsatisfied response rate. Objective: The aim of the study is to review the latest status of the discovery and development of gabapentinoids for the treatment of chronic NP by covering both the marketed and the preclinical/clinical ones. Moreover, it aims to analyze the structure-activity relationship (SAR) of gabapentinoids to facilitate the future design of structurally novel therapeutic agents targeting the VGCC alpha 2 delta subunit. Methods: We searched PubMed Central, Embase, Cochrane Library, Web of Science, Scopus, and Espacenet for the literature and patents on diabetic peripheral neuropathic pain, postherpetic neuralgia, fibromyalgia, voltage-gated calcium channel alpha 2 delta subunit and related therapeutic agents from incipient to June 10, 2021. The SAR of gabapentinoids was analyzed by pharmacophore modeling using the Phase module in the Schrodinger suite. Results: A variety of gabapentinoids were identified as VGCC alpha 2 delta ligands that have ever been under development to treat chronic NP. Among them, four gabapentinoids are marketed, one is in the active late clinical trials, and eight have been discontinued. Pharmacophore models were generated using the phase module in the Schrodinger suite, and common pharmacophores were predicted based on pharmacophoric features and analyzed. Conclusion: The latest progress in the discovery and development of gabapentinoids for the treatment of chronic NP was reviewed. Moreover, the structure-activity relationship (SAR) of gabapentinoids has been analyzed by pharmacophore modeling, which will be valuable for the future design of structurally novel therapeutic agents targeting the VGCC alpha 2 delta subunit.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available